Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes

Tri Juli Edi Tarigan,1 Adisti Dwijayanti,2 Susie Setyowati,3 Melva Louisa4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Department of Medical Pharmacy, F...

Full description

Bibliographic Details
Main Authors:	Tarigan TJE, Dwijayanti A, Setyowati S, Louisa M
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-01-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	biosimilar insulin autoantibody zinc transporter 8 antibody hyperglycemia
Online Access:	https://www.dovepress.com/immunogenicity-and-efficacy-of-insulin-glargine-biosimilar-ezelin-vers-peer-reviewed-article-DMSO

Similar Items

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration
by: Samantha Walczuk, et al.
Published: (2024-03-01)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
by: Yiya Wang, et al.
Published: (2022-08-01)

Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
by: L. N. Shitov, et al.
Published: (2019-04-01)

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies
by: Bin Sun, et al.
Published: (2021-06-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022-02-01)

After 100 years of life, is there an insulin crisis? The problem of insulin costs and the opportunity of biosimilar insulins
by: Domenico Cucinotta, et al.
Published: (2023-02-01)

Early Insulin Glargine Initiation in Iranian People With Uncontrolled Type 2 Diabetes: Glycemic Control, and Adverse Events
by: Mohammad Ebrahim Khamseh, et al.
Published: (2018-04-01)

Insulin biosimilars in clinical practice
by: A. F. Verbovoy, et al.
Published: (2022-01-01)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
by: Mamatha Garige, et al.
Published: (2023-03-01)

Effectiveness of Insulin Glargine on Recovery of Patients with Diabetic Ketoacidosis: A Randomized Controlled Trial
by: Jalil Houshyar, et al.
Published: (2015-05-01)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
by: Xiaoli Sheng, et al.
Published: (2019-08-01)

Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
by: Nader ND, et al.
Published: (2020-03-01)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017-04-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-12-01)

Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma
by: N. B. Abramenko, et al.
Published: (2019-09-01)

Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis
by: Li-Jou Yang, et al.
Published: (2022-02-01)

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
by: Victor Enrique Sarmiento-Ortega, et al.
Published: (2023-04-01)

Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes?
by: Rebecca Ohman‐Hanson, et al.
Published: (2024-08-01)

Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015-06-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)

Study of equivalence and comparable immunogenicity of biosimilar insulin aspart in comparison with the registered analogue
by: Т. L. Karonova, et al.
Published: (2022-06-01)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
by: Thomann R, et al.
Published: (2020-07-01)

A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo® in Chinese healthy male participants
by: Xiaoli Li, et al.
Published: (2024-08-01)

Biosimilar insulins – What a clinician needs to know?
by: Sujoy Ghosh, et al.
Published: (2019-01-01)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
by: Dippel, Franz-Werner, et al.
Published: (2010-01-01)

Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016-07-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
by: Lau IT, et al.
Published: (2017-06-01)

Insulin glargine use and breast cancer: a systematic review and meta-analysis
by: Ibrahim Altedlawi Albalawi, et al.
Published: (2019-03-01)

Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
by: Parag Goyal, et al.
Published: (2021-01-01)

Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
by: Jakobsen Marie, et al.
Published: (2012-09-01)

Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
by: Kaleen N. Hayes, et al.
Published: (2022-05-01)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yunjiao Yang, et al.
Published: (2022-05-01)

rDNA insulin glargine U300 – a critical appraisal
by: Wang F, et al.
Published: (2016-12-01)

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
by: Trevor J. Orchard, et al.
Published: (2017-06-01)

Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy
by: Pešić Milica, et al.
Published: (2007-01-01)

Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries
by: David Beran, et al.
Published: (2025-01-01)

Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
by: Natalya Nikitichna Volevodz, et al.
Published: (2013-03-01)